提醒

提醒专业图表

COMPASS Pathways (CMPS)

NasdaqGS: CMPS · 实时价格 · USD

13.45

+0.16 (1.20%)

收盘价： Aug 14, 2026, 3:59 PM

13.45

+0.00%

盘后: 7:57 PM

1.20% (1D)

买价	9.68
市值	1.86B
营收（TTM）	n/a
净利润（TTM）	-394.19M
贝塔值	2.53
每股收益（TTM）	-3.79
市盈率（TTM）	n/a
预期市盈率	-9.38
市净率（TTM）	21.59
市销率（TTM）	n/a
Earnings Date	Nov 3, 2026

卖价	16.8
成交量	1,283,306
20日均量	3,927,782
开盘价	13.43
前收盘价	13.29
日内区间	13.06 - 13.48
52周区间	3.97 - 15.40
分析师	Strong Buy
目标价	21 (56.13%)
分红	n/a
除息日	n/a

关于 CMPS

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to...

[阅读更多]

行业 Medical Care Facilities

板块 Healthcare

上市日期 Sep 18, 2020

员工人数 156

交易所 NasdaqGS

股票代码 CMPS

官网 https://compasspathways.com

公司完整简介

财务表现

2025年，COMPASS Pathways的营收为0，较上一年的0增长undefined%。净利润为-287.86M，增长85.57%。

财务报表

分析师预测

根据16位分析师的评级，CMPS的平均评级为“Strong Buy”。12个月目标价为21，较最新价格上涨空间56.13%。

股票预测

财报意外

COMPASS Pathways 已于 Aug 5, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， NaN% 同比增长.

每股收益为 -0.36 低于预期 -0.03, ， 12.20% 同比增长.

下次财报发布时间

COMPASS Pathways 计划于以下时间发布财报 Nov 3, 2026, 开盘前。
分析师预计营收为 ... 升级

新闻

1天前 · MarketBeat

Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003

Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adj...

3天前 · Motley Fool

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript

COMP360 shows 39% response rate; commercial launch targeted for H1 2027.

3天前 · MarketBeat

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quart...

5天前 · Market Exclusive

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground C...

1周前 · Simply Wall St.

COMPASS Pathways (CMPS) Could Be 45% Below Fair Value On VA Trial Collaboration

COMPASS Pathways (NasdaqGS:CMPS) just announced a collaboration with the U.S. Department of Veterans Affairs on the PIVOT trial, a multi site study of COMP360 psilocybin in veterans with treatment res...

第 1 页，共 2 页

COMPASS Pathways (CMPS)